Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amcor Plc

Atmos Energy

Franklin Resources

Essex Property Trust

Federal Realty Investment Trust

Coca-Cola

Leggett & Platt

Medtronic

Realty Income Corp

Stanley Black & Decker

Target

T. Rowe Price Group

V.F.

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing. 65 Aristocrats screened as of November 8, 2022 represented all eleven Morningstar sectors. Broker-estimated top-ten net gains ranged 11.21%-36.63%, topped by MDT & ESS.

Walgreens Named November Aristocrats Top Dog

AmerisourceBergen

Fintel reports that Walgreens Boots Alliance, Inc.

Walgreens Boots Alliance (WBA) Reports Lower Stake in AmerisourceBergen (ABC) after Stock Sale & Share Repurchase

Walgreens Boots Alliance Strengthens Commitment to Expand Disability Representation

Walgreens Boots Alliance Announces Offering of 10 Million Shares of AmerisourceBergen Corporation

Walgreens will put up $3.5 billion of the $8.9 billion deal to add Summit Health-CityMD to it's primary care portfolio.

Walgreens combines VillageMD and CityMD in $8.9 billion deal

Cigna

Walgreens backed doctor-staffed clinic operator VillageMD is buying Summit Health in a deal valued at $8.9 billion to expand doctor-staffed clinics across the country.

Walgreens-Backed VillageMD And Cigna's Evernorth To Buy Summit Health For Nearly $9 Billion

The combination will create a larger multispecialty platform for patient care.

Walgreens Unit VillageMD Combines with Summit Health. The Stock Is Up.

VillageMD announced Monday and agreement to buy urgent care provider Summit Health-CityMD in a deal valued at $8.9 billion, with help from investments from Walgreens Boots Alliance Inc. WBA, +4.77% and Cigna Corp CI, +0.12% affiliate Evernorth. As part of the deal, drugstore and health care services company Walgreens will invest $3.5 billion worth of equity and debt, and will remain the largest shareholder of VillageMD with 53% ownership.

VillageMD to buy Summit Health-CityMD in an $8.9 billion deal, including $3.5 billion Walgreens investment

Primary care provider VillageMD, which is backed by Walgreens Boots Alliance Inc , is buying urgent care provider Summit Health in a deal valued at $9 billion, as the second-largest U.S. pharmacy chain expands its healthcare footprint.

Walgreens-backed VillageMD to buy Summit Health in $9 billion deal

VillageMD Acquires Summit Health-CityMD, Creating One of the Largest Independent Provider Groups in the U.S.

Intel

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

These Dow Jones Industrial Average stocks, which sport an average yield of 5.91%, can really pack a punch for income seekers.

Want $300 in Quarterly Dividend Income? Invest $20,400 in These 3 High-Yield Dow Stocks

A unit of Walgreens Boots Alliance Inc. WBA, +3.72%  is nearing a deal to combine with a big owner of medical practices and urgent-care centers in a transaction worth roughly $9 billion including debt, according to people familiar with the matter, the latest in a string of acquisitions by big consumer-focused companies aiming to delve deeper into medical care.

Walgreens subsidiary nears $9 billion deal to merge with Summit Health

Village Practice Management would combine with Summit Health, the parent company of CityMD urgent-care centers, in an agreement that could be reached as early as Monday, people familiar with the matter said.

Walgreens Unit Close to Roughly $9 Billion Deal With Summit Health

Hanesbrands

Home Depot

JPMorgan Chase & Co

Lowe's

McCormick

Pinterest

Snap

STORE Capital

Wells Fargo

October turned out to be the best month for the Dow Jones Industrial Average in a long time.

Now's a Good Time to Buy Stocks

AbbVie

Both these companies pay a dividend, but the similarities stop there.

Better Buy: AbbVie vs. Walgreens Boots Alliance

Walgreens Teams Up with Its Health Corners and Clinic Partners to Expand Access to Complimentary Diabetes Services during Diabetes Awareness Month

CVS Health

Walmart

CVS Health Corp (NYSE:CVS), Walgreens Boots Alliance Inc (NASDAQ:WBA), and Walmart Inc (NYSE:WMT) have agreed to pay about $13.8 billion to resolve thousands of US state and local lawsuits accusing the pharmacy chains of mishandling opioid pain drugs. CVS said on Wednesday it had agreed to pay about $5 billion over 10 years, and Walgreens said that it had agreed to pay about $5.7 billion over 15 years.

Walmart, Walgreens and CVS, agree to pay $13.8B to settle US opioid claims

Boeing

Goldman Sachs

Microsoft

NIKE

When the U.S. Bureau of Economic Analysts posted real gross domestic product ( GDP ) growth of 2.6% on an annualized basis, stocks in the Dow Jones index rallied. Indeed, worries of a recession at this moment have been quashed by this impressive report, leading to strength in most Dow stocks relative to other sector such as tech, for example, of late.

Hurry! 7 Pitiful Dow Stocks to Sell Before 2022 Ends.

CVS announced Wednesday it had agreed to pay $5 billion, while Walgreens and Walmart also reportedly reached billion-dollar settlement deals.

CVS, Walgreens And Walmart Agree To Pay More Than $10 Billion To Settle Opioid Claims

Walgreens Announces Agreement in Principle for Multi-State Opioid Settlement Framework

Walgreens Boots Alliance WBA, -0.66% said Wednesday it will pay about $5 billion as part of a framework to resolve "a substantial majority" of opioid-related lawsuits with some states and Native American tribes, according to a securities filing. That includes $4.79 billion over 15 years to participating states and $154.5 million over 15 years to participating tribes.

Walgreens to pay about $5 billion to resolve some opioid lawsuits with states and tribes

CVS, Walgreens and Walmart – the nation's three largest retail U.S. pharmacies — have agreed “in principle” to pay $12 billion in a massive global settlement to resolve claims they contributed to the opioid epidemic.

Reports: CVS, Walgreens And Walmart Agree To $12 Billion Opioid Settlement

CVS Health Corp , Walgreens Boots Alliance Inc and Walmart Inc have tentatively agreed to pay more than $12 billion to resolve thousands of state and local government lawsuits accusing the chains of mishandling opioid painkillers, Bloomberg News reported on Tuesday.

CVS, Walmart, Walgreens reach tentative $12 bln Opioid pact - Bloomberg News

Cisco Systems

Disney

Procter & Gamble

Representing some of the biggest names across various industries, the companies listed in the Dow Jones usually facilitate a great starting point for newbie investors. Featuring established track records, Dow stocks typically deliver the goods.

7 Dow Stocks Set to Soar From 52-Week Lows

ABB Ltd.

Arbor Realty Trust

Enterprise Products Partners

eXp World Holdings Inc

Innovative Industrial Properties

Kinder Morgan

Main Street Capital

Magellan Midstream Partners

Philip Morris

Sanofi

Starwood Property

A February 2, 2022, Kiplinger Today special report headlined, "Potent Picks to Profit in 2022,” featured 97 dividend-fetching stocks from 118 in that article per YCharts 10/28/22 data. Article-titles were: "65 Best Dividends"; "15 Value Stocks"; "15 Best Mid-Caps"; "10 European Plays"; "9 High Yields"; and "6 Sturdy Defensive Stocks."

13 Potent Picks Are November's Ideal Dividend Buys

News for Walgreens Stock (WBA)